Search Result

Results for "

tumor imaging

" in MedChemExpress (MCE) Product Catalog:

By Targets:	ADC Linker (2) Amino Acid Derivatives (1) Aminopeptidase (2) Apoptosis (2) Biochemical Assay Reagents (3) Bombesin Receptor (1) CD22 (1) Cholecystokinin Receptor (1) Cholinesterase (ChE) (1) Cytochrome P450 (1) Drug Metabolite (1) EGFR (2) Endogenous Metabolite (2) Estrogen Receptor/ERR (1) FAP (9) Fluorescent Dye (10) HDAC (1) HSP (1) Integrin (2) Interleukin Related (1) Ligands for Target Protein for PROTAC (1) Melanocortin Receptor (2) PARP (2) PD-1/PD-L1 (1) PSMA (5) Radionuclide-Drug Conjugates (RDCs) (9) Ser/Thr Protease (1) Sigma Receptor (1) Somatostatin Receptor (1) TrxR (1)
By Research Areas:	Cancer (73) Inflammation/Immunology (2) Metabolic Disease (2) Neurological Disease (1)
Oligonucleotides:	Aptamers (2)

Inhibitors & Agonists

Fluorescent Dye

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

Natural
Products

Oligonucleotides

Targets Recommended: TNF Receptor BRK

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-159045

F-SAHA p-Fluoro-SAHA	HDAC	Cancer
F-SAHA is a HDAC inhibitor (HDACi) and its ¹⁸F labeled derivative can be used in tumor imaging research .

HY-137331

FAPI-46 1 Publications Verification	FAP	Cancer
FAPI-46 is a quinoline-based fibroblast activation protein (FAP)-targeted radiotracer. FAPI-46 has higher tumor uptake and prolonged tumor accumulation. FAPI-46 can be used for tumor imaging of a multitude of different cancers .

HY-P5128

DOTA-JR11 Satoreotide tetraxetan	Somatostatin Receptor Radionuclide-Drug Conjugates (RDCs)	Cancer
DOTA-JR11 is a somatostatin receptor 2 （SSTR2）antagonist. DOTA-JR11 can be labeled by 68Ga, used for paired imaging in neuroendocrine tumors (NETs) research .

HY-141464

Fmoc-L-Asn(beta-D-GlcNAc(Ac)3)-OH Fmoc-Asn(Ac3AcNH-beta-Glc)-OH	Amino Acid Derivatives	Cancer
Fmoc-L-Asn(beta-D-GlcNAc(Ac)3)-OH (Fmoc-Asn(Ac3AcNH-beta-Glc)-OH) can be used in the synthesis of silicon-fluoride acceptor (SiFA) derivatized octreotate derivatives. SiFA-octreotate analogues, as tumor imaging agents, are useful tool for the research of positron emission tomography (PET) .

HY-75706

N-Descyclopropanecarbaldehyde Olaparib	PARP Ligands for Target Protein for PROTAC	Cancer
N-Descyclopropanecarbaldehyde Olaparib is an analogue of Olaparib (HY-10162) containing DOTA moiety. N-Descyclopropanecarbaldehyde Olaparib is a PARP inhibitor used for synthesizing novel dual EGFR and PARP PROTAC, DP-C-4 . N-Descyclopropanecarbaldehyde Olaparib can be radiolabeled F-18 or fluorophore for positron emission tomography (PET) or optical imaging in several types of tumor .

HY-D1719

Cypate	Fluorescent Dye	Others
Cypate, a cyanine dye, is a near infrared (NIR) fluorescent probe for in vivo tumor imaging .

HY-163545

Tc-Me2P	Others	Cancer
Tc-Me2P is a 99MTC-labeled acrylamide (PnAO) derivative that contains two 4-methyl-2-nitroimidazole groups. The primary activity of Tc-Me2P is as an imaging agent for tumor hypoxia. By specifically binding to hypoxic regions in tumor tissue, it can be used for single photon emission computed tomography (SPECT) and positron emission tomography (PET) imaging to detect hypoxia in tumors. Tc-Me2P can be used to study the targeting of different chemical structures in tumors and normal tissues .

HY-149931

BMV109	Fluorescent Dye	Cancer
BMV109 is a quenched probe that becomes fluorescent when cleaved and covalently bound by active cathepsin proteases. BMV109 can be exploited for tumor imaging .

HY-D2281

[99mTc]Tc-6–1	FAP	Cancer
[99m Tc]Tc-6-1, a ^99mTc-labeled FAPI-46 derivative, is a specific fibroblast activation protein (FAP)-targeted radiotracer. [99m Tc]Tc-6-1 exhibits good tumor uptake and acts as a promising molecular tracer for FAP tumor imaging .

HY-158251

BIBD-300	Others	Cancer
BIBD-300 is a PARP-1 imaging agent with high affinity for PARP-1. BIBD-300 can accurately localize C6 and U87MG tumors, which can be used for research in the diagnosis of breast cancer, prostate cancer, glioma, and liver cancer .

HY-149298

PSMA-IN-2	PSMA	Cancer
PSMA-IN-2 is an inhibitor of PSMA with a K_i value of 1.07 nM. PSMA-IN-2 displays favorable in vivo NIR imaging (λ_EM = 1088 nm, λ_ex = 808 nm), and can be used for NIRII image-guided tumor resection surgery in PSMA-positive tumor-bearing mice .

HY-W034551

DOTA-tri(t-butyl ester)	Radionuclide-Drug Conjugates (RDCs)	Others Cancer
DOTA-tri(t-butyl ester) can be used in the synthesis of generations 3 (G3) nanoglobular magnetic resonance imaging (MRI) contrast agents for MR angiography and tumor angiogenesis imaging .

HY-156982

Parpi	Others	Cancer
Parpi is a PET radioactive tracer with low lipotropy. Parpi can be used as a tumor imaging agent .

HY-136404

Melanin probe-1	Others	Cancer
Melanin probe-1 is an ¹⁸F-picolinamides based PET probe. Melanin probe-1 can be used for PET imaging of malignant melanoma. Melanin probe-1 exhibits high tumor targeting efficiency, excellent tumor imaging contrasts, desirable biodistribution patterns, and good in vivo stability .

HY-P1043A

NGR peptide Trifluoroacetate 1 Publications Verification	Aminopeptidase	Cancer
NGR peptide Trifluoroacetatecontaining the Asn-Gly-Arg (NGR) motif. NGR peptide Trifluoroacetate binds to APN/CD13. NGR peptide Trifluoroacetate is directly conjugated to imaging agents that can be used for tumor imaging .

HY-P1043

NGR peptide	Aminopeptidase	Cancer
NGR peptide containing the Asn-Gly-Arg (NGR) motif. NGR peptide binds to APN/CD13. NGR peptide is directly conjugated to imaging agents that can be used for tumor imaging .

HY-P10292

NOTA-Pep-1L	Radionuclide-Drug Conjugates (RDCs) Interleukin Related	Cancer
NOTA-Pep-1L specifically targets the IL13RA2 receptor for tumor imaging .

HY-150979

Gd-NMC-3	Fluorescent Dye	Cancer
Gd-NMC-3 is a near-infrared fluorescence/magnetic resonance (NIRF/MR) bimodal imaging probe. Gd-NMC-3 shows high resolution and sensitivity in tumor imaging with good biocompatibility, indicating huge application potential .

HY-47979A

FAP-IN-2 TFA	FAP	Others Cancer
FAP-IN-2 TFA is a ^99mTc-labeled isonitrile-containing FAP inhibitor derivative that can be used for tumor imaging .

HY-D1719A

Cypate hydrochloride	Fluorescent Dye	Cancer
Cypate is a near-infrared fluorescent dye that belongs to the family of photosensitizers. Cypate has high photostability and optical properties, and is often used in near-infrared optical imaging, as well as optical imaging, tumor marking, and drug delivery. In addition, Cypate is also used as a molecular probe and combined with targeting molecules (such as CBT or small interfering RNA) to achieve efficient detection and imaging of specific cells or tissues .

HY-47979

FAP-IN-2	FAP	Others Cancer
FAP-IN-2 is a derivative of ^99mTc-labeled isonitrile-containing fibroblast activation protein (FAPI) inhibitor, that can be used for tumor imaging .

HY-162051

CYP1B1-IN-6	Cytochrome P450	Cancer
CYP1B1-IN-6 (compound 19) is a fluorescence molecular probes which inhibits CYP1B1 activity. CYP1B1-IN-6 can identify tumor sites in fluorescence imaging and photoacoustic imaging modes .

HY-161074

PNT6555	FAP	Cancer
PNT6555 is a fibroblast activation protein-α (FAP) inhibitor. PNT6555 has antitumor activity. PNT6555 can be used for imaging of FAP-positive tumors .

HY-128890

DOTA-NHS-ester 1 Publications Verification	ADC Linker	Cancer
DOTA-NHS-ester is a linker for affibody molecules and is applied in small animals PET, SPECT, and CT. DOTA-NHS-ester can be used to label radiotherapeutic agents or imaging probes for the detection of tumors .

HY-W422400

Fluoroglutamine (2S,4R)	Biochemical Assay Reagents	Others Cancer
Fluoroglutamine (2S,4R) is a fluorinated derivative of glutamine. As a substrate for various aminotransferases, Fluoroglutamine (2S,4R) can be used as a tracer for positron emission tomography (PET) imaging. Fluoroglutamine (2S,4R) is applied in the research fields of tumor metabolism and imaging .

HY-153432

TRV-7019	Cholinesterase (ChE)	Neurological Disease Cancer
TRV-7019 is a BBB-penetrable radioligand for brain imaging that target butyrylcholinesterase. TRV-7019 can be used for the diagnosis of an amyloid disease, multiple sclerosis, a brain tumor, or butyrylcholinesterase activity .

HY-122607

DPA-714	Others	Inflammation/Immunology Cancer
DPA-714 is a high affinity translocator protein (TSPO) ligand (K_i=7 nM), which is designed with a fluorine atom in its structure, allowing labelling with fluorine -18 and in vivo imaging using positron emission tomography. ^18FDPA-714 successfully evaluates for the specific imaging of inflammation in various models of neuroinflammation and in a brain tumor model .

HY-152102

BTCy	Fluorescent Dye	Cancer
BTCy is a near-infrared (NIR) fluorescence probe with polarity-responsive and cell plasma membrane-targeting properties. BTCy can be used for in vivo imaging of tumor tissue (λ_ex = 561 nm, λ_em = 600-700 nm) .

HY-N7755

Estradiol 3-(β-D-Glucuronide) (sodium)	Estrogen Receptor/ERR	Cancer
Estradiol 3-(β-D-Glucuronide) sodium is the glucuronic acid derivative of estradiol (HY-B0141). Estradiol 3-(β-D-Glucuronide) sodium is radiolabeled for use in tumor imaging and biodistribution studies .

HY-136201

Sodium Glucoheptonate	Others	Cancer
Sodium Glucoheptonate is used as a kit for radio-labeling with Tc-99m. Tc-99m glucoheptonate is kidney- and brain-imaging agent, and can be used in brain-tumor detection .

HY-D2334

AlF-NOTA-c-d-VAP	Radionuclide-Drug Conjugates (RDCs) HSP	Cancer
AlF-NOTA-c-d-VAP is a peptide positron emission tomography (PET) probe that used for targeted tumor imaging of GRP78. AlF-NOTA-c-d-VAP demonstrates high stability in vitro and in vivo .

HY-147057

FAP-2286 1 Publications Verification	FAP	Cancer
FAP-2286 is a potent and selective FAP-binding peptide coupled to a radionuclide chelator with a mean IC₅₀ value of 2.7 nM for binding to FAP. FAP-2286 can chelate radionuclides for imaging or therapeutic applications and has a strong effect on FAP-positive tumors. FAP-2286 can be used for FAP-positive tumor research .

HY-162958

Photosensitizer-6	Apoptosis TrxR	Cancer
Photosensitizer-6 (Compound 4) is a gold (I) complex and exhibits inhibitory activity against TrxR. Photosensitizer-6 induces apoptosis in 4T1 cell, targets and eradicates tumors through chemo-phototherapy and immunogenic cell death under light exposure. Photosensitizer-6 can be used for tumor imaging .

HY-155485

Abi-DZ-1	Others	Cancer
Abi-DZ-1 is a potential multifunctional theranostic agent via the HIF1α/OATPs Pathway. Abi-DZ-1 can be used in the research of tumor-targeted imaging and precision therapy .

HY-121659

DCFBC	Others	Cancer
DCFBC is a prostate-specific membrane antigen (PSMA) inhibitor for small animal positron emission tomography (PET) imaging. [18F]DCFBC was prepared by reacting fluorine-18 labeled phenyl bromide with the precursor (S)-2-[3-[(R)-1-carboxy-2-thiolethyl]urea]-glutaric acid in ammonia-saturated methanol at 60°C for 10 min and then purified by C-18 reversed-phase HPLC. [18F]DCFBC was injected via the tail vein in severe combined immunodeficient mice for in vitro biodistribution or imaging. For in vitro biodistribution studies, mice were sacrificed at 5, 15, 30, 60, and 120 min after injection, and tumors, blood, and major organs were collected, weighed, and radioactivity was counted. Imaging was performed using a GE eXploreVista small animal PET scanner, collecting 12 consecutive 10-min frames. Results showed that the radiochemical yield of [18F]DCFBC averaged 16±6% (n=8) from 4-[18F]fluorophenyl bromide. Specific radioactivity ranged from 13 to 133 GBq/Amol (350-3600 Curie/mmol) with an average of 52 GBq/Amol (1392 Curie/mmol; n=6). Biodistribution and imaging studies showed high uptake of [18F]DCFBC in PIP tumors and almost no uptake in FLU tumors. High radiopharmaceutical uptake was also seen in the kidney and bladder; however, radioactivity washout from these organs was faster than from the PIP tumors. Maximum PIP tumor uptake was reached at 60 min post-injection at 8.16±2.55% injected dose/g and decreased to 4.69±0.89 at 120 min post-injection. The PIP tumor-to-muscle ratio was 20 at 120 min post-injection. Based on mouse biodistribution, the dose-limiting organ was the kidney (estimated human absorbed dose: 0.05 mGy/MBq; 0.2 rad/mCi). Conclusions: [18F]DCFBC localizes specifically to PSMA+ expressing tumors in mice and is suitable for small animal PET imaging. This novel radiopharmaceutical is an attractive candidate for further study in PET imaging of prostate cancer.

HY-123733A

MIP-1095 TFA RPS-001 TFA	PSMA	Cancer
MIP-1095 (RPS-001) TFA is a potent inhibitor of PSMA with good biodistribution and efficient targeting of tumor lesions. In applications, MIP-1095 TFA will be isotopically labeled ( ¹³¹I labeled) as an imaging probe to indicate tumor progression. And ¹³¹I-MIP-1095 showed higher renal uptake in mice .

HY-164475

PARP1-IN-29	PARP	Cancer
PARP1-IN-29 is an orally active PARP-1 inhibitor with an IC₅₀ value of 6.3 nM. PARP1-IN-29, after being labeled with [18F], can be used for positron emission tomography (PET) imaging, specifically targeting PARP-1 in tumors. PARP1-IN-29 is applicable in the fields of oncology and imaging research, particularly for detecting PARP-1 activity in cancer .

HY-128890B

DOTA-NHS-ester TFA 1 Publications Verification	ADC Linker Biochemical Assay Reagents	Cancer
DOTA-NHS-ester (TFA) is used as a linker for affibody molecules, and it can be employed in small animal positron emission tomography (PET), single photon emission computed tomography (SPECT), and CT scanning. DOTA-NHS-ester can be used to label radiotracers or imaging probes for tumor detection .

HY-D1716

S0456	Fluorescent Dye	Cancer
S0456 is a near-infrared (NIR) fluorescent dye that can be used for synthesize Pafolacianine (HY-139579). S0456 binds to the folate receptor (FR). S0456 can be used as a tumor-specific optical imaging agent. The excitation wavelength is 788 nM and emission wavelength is 800 nM .

HY-155486

HCy-AAN-Bio	Others	Cancer
HCy-AAN-Bio is a tumor-targeted hemicyanine (HCy) probe for Fluorescent/photoacoustic (FL/PA) imaging of legumain in vivo. Legumain can specifically cleave HCy-AAN-Bio with the generation of FL/PA signal. HCy-AAN-Bio is a powerful tool for early diagnosis of associated cancer .

HY-17026E

Gemcitabine triphosphate trisodium dFdCTP trisodium	Endogenous Metabolite	Cancer
Gemcitabine triphosphate (trisodium) is one of the two nucleoside metabolites of Gemcitabine (HY-17026) in cells. The other is active diphosphate (dFdDTP). Gemcitabine triphosphate can be used as a standard in radio-labeled probe imaging studies, to identify tumors sensitive to Gemcitabine, and to evaluate Gemcitabine uptake and retention by cells .

HY-141729

Biotin-NH-PSMA-617	Fluorescent Dye	Cancer
Biotin-NH-PSMA-617 is a biotin-tagged PSMA-617. PSMA-617 is a small molecule targeting the prostate-specific membrane antigen (PSMA), which is directly expressed by the tumor cells .

HY-W088413A

DOTA-amide dihydrate	Biochemical Assay Reagents	Cancer
DOTA-amide (dihydrate) is a Bifunctional Chelators (BFCs). DOTA-amide (dihydrate) binds to the Affibody molecule ZHER2:S1. Its complex binds specifically to HER2 and can be used to detect bone metastases, which are common in prostate cancer .

HY-17026A

Gemcitabine triphosphate dFdCTP	Drug Metabolite Endogenous Metabolite	Cancer
Gemcitabine triphosphate (dFdCTP) is one of the two nucleoside metabolites of Gemcitabine (HY-17026) in cells. The other is active diphosphate (dFdDTP). Gemcitabine triphosphate can be used as a standard in radio-labeled probe imaging studies, to identify tumors sensitive to Gemcitabine, and to evaluate Gemcitabine uptake and retention by cells .

HY-P5292

HYNIC-iPSMA	PSMA	Cancer
HYNIC-iPSMA is a ligand for molecular imaging of tumors. Hynic-ipsma consists of two components: HYNIC (6-hydrazinonicotinamide) and iPSMA (Inhibitor of Prostate-Specific Membrane Antigen). HYNIC is a compound used to attach radioactive isotopes to targeted molecules. iPSMA is a specific inhibitor used to inhibit prostate-specific membrane antigen (PSMA). 68GA-labeled iPSMA has been used to detect prostate cancer by PET imaging. The further 99mTc-EDDA/HYNIC-iPSMA has excellent specificity and sensitivity .

HY-P5292A

HYNIC-iPSMA TFA	PSMA	Cancer
HYNIC-iPSMA TFA is a ligand for molecular imaging of tumors. Hynic-ipsma consists of two components: HYNIC (6-hydrazinonicotinamide) and iPSMA (Inhibitor of Prostate-Specific Membrane Antigen). HYNIC is a compound used to attach radioactive isotopes to targeted molecules. iPSMA is a specific inhibitor used to inhibit prostate-specific membrane antigen (PSMA). 68GA-labeled iPSMA has been used to detect prostate cancer by PET imaging. The further 99mTc-EDDA/HYNIC-iPSMA TFA has excellent specificity and sensitivity .

HY-D1464

CH1055 1 Publications Verification	Fluorescent Dye	Cancer
CH1055 is a NIR-II fluorophore based on a synthetic 970-Da organic molecule. CH1055 is a rapidly excreted dye (∼90% excreted through the kidneys within 24 h). CH1055 also allows targeted molecular imaging of tumors in vivo when conjugated with anti-EGFR Affibody .

HY-P99289

Epratuzumab Antibody hLL 2; Anti-Human CD22 Recombinant Antibody	CD22	Inflammation/Immunology Cancer
Epratuzumab (Antibody hLL 2) is an anti-CD22 IgG1 monoclonal antibody. Epratuzumab is also a tumor-imaging agent and an immunomodulatory agent. Epratuzumab can induce CD22 phosphorylation. Epratuzumab has been used to research non-Hodgkin’s lymphomas (NHL) and certain autoimmune diseases .

HY-156124

Sigma-2 Radioligand 1	Sigma Receptor	Cancer
Sigma-2 Radioligand 1 (compound 1) is a Sigma-2 selective ligand. Sigma-2 Radioligand 1 has good biodistribution in mice and good in vivo activity in rats. [18F] Modified Sigma-2 Radioligand 1 for visualization of tumors in micro-PET/CT imaging, exhibiting high tumor uptake and tumor-to-background ratio. Experiments show that Sigma-2 Radioligand 1 binds highly specifically in U87MG glioma xenografts .

HY-128643

FAPI-4 Maximum Cited Publications 21 Publications Verification	FAP	Cancer
FAPI-4 is a potent fibroblast activation protein (FAP) inhibitor for the targeting FAP. FAPI-4 can be used in cancer research. ⁶⁸Ga-FAPI-4 PET/CT is a promising new diagnostic method for imaging various kinds of cancer, with good tumor-to-background contrast ratios .

Cat. No.	Product Name	Type

HY-D1716

S0456	Fluorescent Dyes/Probes
S0456 is a near-infrared (NIR) fluorescent dye that can be used for synthesize Pafolacianine (HY-139579). S0456 binds to the folate receptor (FR). S0456 can be used as a tumor-specific optical imaging agent. The excitation wavelength is 788 nM and emission wavelength is 800 nM .

HY-D2281

[99mTc]Tc-6–1	Dyes
[99m Tc]Tc-6-1, a ^99mTc-labeled FAPI-46 derivative, is a specific fibroblast activation protein (FAP)-targeted radiotracer. [99m Tc]Tc-6-1 exhibits good tumor uptake and acts as a promising molecular tracer for FAP tumor imaging .

HY-150979

Gd-NMC-3	Fluorescent Dyes/Probes
Gd-NMC-3 is a near-infrared fluorescence/magnetic resonance (NIRF/MR) bimodal imaging probe. Gd-NMC-3 shows high resolution and sensitivity in tumor imaging with good biocompatibility, indicating huge application potential .

HY-162051

CYP1B1-IN-6	Fluorescent Dyes/Probes
CYP1B1-IN-6 (compound 19) is a fluorescence molecular probes which inhibits CYP1B1 activity. CYP1B1-IN-6 can identify tumor sites in fluorescence imaging and photoacoustic imaging modes .

HY-D2334

AlF-NOTA-c-d-VAP	Dyes
AlF-NOTA-c-d-VAP is a peptide positron emission tomography (PET) probe that used for targeted tumor imaging of GRP78. AlF-NOTA-c-d-VAP demonstrates high stability in vitro and in vivo .

HY-D2285

MOR-CES2	Fluorescent Dyes/Probes
MOR-CES2 is a near-infrared fluorescent probe (E_x= 630 nm, E_m=735 nm) capable of identifying cancer cells and tissues, as well as exhibiting a sensitive response to inflammation. MOR-CES2 holds potential as an efficient imaging tool in assisting surgical resection of CES2-related tumors .

Cat. No.	Product Name	Type

HY-W088413A

DOTA-amide dihydrate	Chelators
DOTA-amide (dihydrate) is a Bifunctional Chelators (BFCs). DOTA-amide (dihydrate) binds to the Affibody molecule ZHER2:S1. Its complex binds specifically to HER2 and can be used to detect bone metastases, which are common in prostate cancer .

HY-100133A

DOTA-ADIBO TFA	Chelators
DOTA-ADIBO TFA is a DOTA-derived bifunctional chelator (BFC) that allows drug conjugation via an uncatalyzed, copper-free cycloaddition reaction. DOTA-ADIBO TFA enables the construction of fusion chelator systems that can be further used to synthesize radiotracers after Cu[64] modification. Positron emission tomography imaging of tumors expressing integrin αvβ6 .

Cat. No.	Product Name	Target	Research Area

HY-P5128

DOTA-JR11 Satoreotide tetraxetan	Somatostatin Receptor Radionuclide-Drug Conjugates (RDCs)	Cancer
DOTA-JR11 is a somatostatin receptor 2 （SSTR2）antagonist. DOTA-JR11 can be labeled by 68Ga, used for paired imaging in neuroendocrine tumors (NETs) research .

HY-P1043A

NGR peptide Trifluoroacetate 1 Publications Verification	Aminopeptidase	Cancer
NGR peptide Trifluoroacetatecontaining the Asn-Gly-Arg (NGR) motif. NGR peptide Trifluoroacetate binds to APN/CD13. NGR peptide Trifluoroacetate is directly conjugated to imaging agents that can be used for tumor imaging .

HY-P6083

RTSPSSR	Peptides	Others Cancer
RTSPSSR is synthesized peptide, which binds specifically to claudin-1 and visulizes the CRC tumor in mice, through near-infrared fluorescence imaging .

HY-P5292A

HYNIC-iPSMA TFA	PSMA	Cancer
HYNIC-iPSMA TFA is a ligand for molecular imaging of tumors. Hynic-ipsma consists of two components: HYNIC (6-hydrazinonicotinamide) and iPSMA (Inhibitor of Prostate-Specific Membrane Antigen). HYNIC is a compound used to attach radioactive isotopes to targeted molecules. iPSMA is a specific inhibitor used to inhibit prostate-specific membrane antigen (PSMA). 68GA-labeled iPSMA has been used to detect prostate cancer by PET imaging. The further 99mTc-EDDA/HYNIC-iPSMA TFA has excellent specificity and sensitivity .

HY-P4116

pH-Low Insertion Peptide pHLIP	Peptides	Metabolic Disease Cancer
pH-Low Insertion Peptide (pHLIP) is a short, pH-responsive peptide capable of inserting across a cell membrane to form a transmembrane helix at acidic pH. pH-Low Insertion Peptide targets the acidic tumor microenvironment for tumors at early and metastatic stages with high specificity, used as a specific ligand. pH-Low Insertion Peptide successfully modify polylysine polymers to have the pH-responsive capability. pH-Low Insertion Peptide-based targeting of cancer presents an opportunity to monitor metabolic changes, and to selectively deliver imaging and therapeutic agents to tumors .

HY-114133

Depreotide	Peptides	Cancer
Depreotide is a nove tumor tarcer, can be complexed with technetium-99m ( ^99mTc-depreotide) for optimal imaging properties. ^99mTc-depreotide somatostain receptor imaging has been playing an important role in medical diagnosis research .

HY-P1043

NGR peptide	Aminopeptidase	Cancer
NGR peptide containing the Asn-Gly-Arg (NGR) motif. NGR peptide binds to APN/CD13. NGR peptide is directly conjugated to imaging agents that can be used for tumor imaging .

HY-P10292

NOTA-Pep-1L	Radionuclide-Drug Conjugates (RDCs) Interleukin Related	Cancer
NOTA-Pep-1L specifically targets the IL13RA2 receptor for tumor imaging .

HY-P10232

Hynic-toc HYNIC-Tyr3-octreotide	Peptides	Cancer
Hynic-toc (HYNIC-Tyr3-octreotide), a octreotide derivative, can be conjugated with radioactive element for tumor imaging .

HY-P5292

HYNIC-iPSMA	PSMA	Cancer
HYNIC-iPSMA is a ligand for molecular imaging of tumors. Hynic-ipsma consists of two components: HYNIC (6-hydrazinonicotinamide) and iPSMA (Inhibitor of Prostate-Specific Membrane Antigen). HYNIC is a compound used to attach radioactive isotopes to targeted molecules. iPSMA is a specific inhibitor used to inhibit prostate-specific membrane antigen (PSMA). 68GA-labeled iPSMA has been used to detect prostate cancer by PET imaging. The further 99mTc-EDDA/HYNIC-iPSMA has excellent specificity and sensitivity .

HY-P5520

GB-6	Bombesin Receptor Radionuclide-Drug Conjugates (RDCs)	Cancer
GB-6 is a short linear peptide that targets the gastrin releasing peptide receptor (GRPR). GRPR is overexpressed in pancreatic cancer. Based on the tumor selectivity and tumor-specific accumulation properties of GB-6, GB-6 labeled with near infrared (NIR) fluorescent dyes or radionuclide netium-99m (99mTc) can be used as a high-contrast imaging probe. GB-6 has excellent in vivo stability, with tumor to pancreatic and intestinal fluorescence signal ratios of 5.2 and 6.3, respectively, in SW199 0 subcutaneous xenograft models. GB-6 can rapidly target tumors and accurately delineate tumor boundaries, which has broad application prospects .

HY-P4116A

pH-Low Insertion Peptide TFA pHLIP TFA	Peptides	Metabolic Disease Cancer
pH-Low Insertion Peptide TFA (pHLIP TFA) is a short, pH-responsive peptide capable of inserting across a cell membrane to form a transmembrane helix at acidic pH. pH-Low Insertion Peptide TFA targets the acidic tumor microenvironment for tumors at early and metastatic stages with high specificity, used as a specific ligand. pH-Low Insertion Peptide TFA successfully modifys polylysine polymers to have the pH-responsive capability. pH-Low Insertion Peptide TFA -based targeting of cancer presents an opportunity to monitor metabolic changes and to selectively deliver imaging and therapeutic agents to tumors .

HY-P5018

NOTA-AE105	Ser/Thr Protease Peptides	Cancer
NOTA-AE105 is an PET ligand of urokinase-type plasminogen activator receptor (uPAR), which can be radiolabeled by ⁶⁴Cu and ⁶⁸Ga. ⁶⁸Ga-NOTA-AE105 and ⁶⁴Cu-NOTA-AE105 shows high image contrast, resulting in clear tumor delineation .

HY-P2336

CCZ01048	Melanocortin Receptor	Cancer
CCZ01048, a α-melanocyte-stimulating hormone (α-MSH) analogue, exhibits high binding affinity to melanocortin 1 receptor (MC1R) with a K_i of 0.31 nM. CCZ01048 shows rapid internalization into B16F10 melanoma cells and high in vivo stability. CCZ01048 is a promising candidate for PET imaging of malignant melanoma .

HY-P2336A

CCZ01048 TFA	Melanocortin Receptor	Cancer
CCZ01048 TFA, a α-MSH analogue, exhibits high binding affinity to melanocortin 1 receptor (MC1R) with a K_i of 0.31 nM. CCZ01048 TFA shows rapid internalization into B16F10 melanoma cells and high in vivo stability. CCZ01048 TFA is a promising candidate for PET imaging of malignant melanoma .

HY-P5290

HYNIC-PSMA	PSMA	Cancer
HYNIC-PSMA is a ligand for molecular imaging of tumors. Hynic-psma consists of two components: HYNIC (6-hydrazinonicotinamide) and PSMA (Prostate-Specific Membrane Antigen). HYNIC is a compound used to attach radioactive isotopes to targeted molecules, such as ¹⁸⁸Re-HYNIC-PSMA. PSMA is a membrane antigen that is specifically expressed on the surface of prostate cancer cells. HYNIC-PSMA can be used in prostate cancer research .

HY-P1654

A20FMDV2	Integrin	Cancer
A20FMDV2 is a selective αvβ6 integrin inhibitor (IC₅₀: 3 nM), with an activity 1,000-fold more selective for αvβ6 than for other RGD-directed integrins (αvβ3, αvβ5, and α5β1). A20FMDV2 can be derived from the foot-and-mouth disease virus. A20FMDV2 can be radiolabeled for the PET imaging of αvβ6 integrin-positive tumors .

HY-106244

DOTATATE	Radionuclide-Drug Conjugates (RDCs) Peptides	Cancer
DOTATATE is a DOTA-conjugated peptide. DOTATATE can be labelled with radionuclides for positron emission tomography (PET) imaging and peptide receptor radionuclide research (PRRT) .

HY-106244A

DOTATATE acetate	Radionuclide-Drug Conjugates (RDCs) Peptides	Cancer
DOTATATE acetate is a DOTA-conjugated peptide. DOTATATE acetate can be labelled with radionuclides for positron emission tomography (PET) imaging and peptide receptor radionuclide research (PRRT) .

Cat. No.	Product Name	Target	Research Area

HY-P99289

Epratuzumab Antibody hLL 2; Anti-Human CD22 Recombinant Antibody	CD22	Inflammation/Immunology Cancer
Epratuzumab (Antibody hLL 2) is an anti-CD22 IgG1 monoclonal antibody. Epratuzumab is also a tumor-imaging agent and an immunomodulatory agent. Epratuzumab can induce CD22 phosphorylation. Epratuzumab has been used to research non-Hodgkin’s lymphomas (NHL) and certain autoimmune diseases .

Cat. No.	Product Name		Classification

HY-160045

AP1153 aptamer sodium		Aptamers
AP1153 aptamer sodium is a DNA aptamer that specifically binds to the cholecystokinin receptor CCKBR (Kd: ~15 pM), but does not activate CCKBR-related signaling pathways. AP1153 aptamer sodium is internalized by pancreatic ductal adenocarcinoma (PDAC) cells in a receptor-mediated manner. AP1153 aptamer sodium can bioconjugate to the surface of fluorescent nanoparticles to facilitate nanoparticle delivery to PDAC tumors in vivo .

HY-160066

SYL3C aptamer sodium		Aptamers
SYL3C aptamer sodium is a DNA aptamer that targets the epithelial cell adhesion molecule (EpCAM) on the surface of cancer cells. SYL3C aptamer sodium targets multiple human cancer cell lines including MDA-MB-231, Kato III, HT-29, T47D and SW480. The Kd of SYL3C aptamer sodium against breast cancer cell line MDA-MB-231 and gastric cancer cell line Kato III is 38 nM and 67 nM, respectively. SYL3C aptamer sodium provides stability, high binding affinity, and selectivity for targeted cancer therapy, cancer cell imaging, and circulating tumor cell detection .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

tumor imaging

Inhibitors & Agonists

Fluorescent Dye

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

NaturalProducts

Oligonucleotides

Natural
Products